

Cornell Dots: Ultra-small Silica Nanoparticles as Probes for Image-Driven Clinical Applications

Uli Wiesner

Materials Science & Engineering

ubw1@cornell.edu

COE Council Meeting, April 4, 2014



The Wiesner Research Group

Organic (Polymer)-Inorganic Hybrids with Nanoscale Structures

Aim: Understand the fundamental chemical, thermodynamic and kinetic formation principles enabling general and relatively inexpensive wet-polymer chemistry methodologies for the efficient creation of nano- to multiscale functional materials with novel property profiles

Targeted applications (with collaborators)



diagnostics & nanomedicine



clean water



energy conversion & storage

Overview

The Problem: Lack of Visualization during Cancer Surgery

A Solution: Cornell Dots (C Dots), a Fluorescent Silica Nanoparticle Imaging (Diagnostic) Platform

First inorganic particle of its class and properties to be approved as a an investigational new drug (IND) for clinical use

Clinical Imaging

Whole body mapping

MRI



CT




PET



Large & expensive ($\$10^6$ - 10^7) screening devices
Preoperative/limited intraoperative settings

Minimally Invasive Surgery

Cheap, miniaturized optical imaging equipment available



Optical imaging can be integrated with endoscopes, other hand-held devices (PET gamma/beta probes)

What is missing: optical (fluorescent) probes for use in humans

A solution: What we did differently




- 1. Use of silica as a material: Safe to use**
- 2. Use of extremely small (< 10 nm) particles: “Target or clear”**



Silica as a biocompatible materials platform

Part of the oldest living organisms on this planet

silica nanoparticle platform



Science **278** (1997), 1795

Science **330** (2010), 214

Science **340** (2013), 337

Nature Mater. **6** (2007), 156

Nature **460** (2009), 1110

Y. Piao, U.W. *et al.*, *Adv. Func. Mater.* **18** (2008), 3745


Cornell dots (C dots): "Target or Clear"



M. Bradbury





Kai Ma



First Human Clinical C dot Trial: Melanoma

0 Phase Trial with 5 Patients: Safety Study






Memorial Sloan-Kettering
Cancer Center

M. Bradbury, U.W. *et al.* (2014), submitted



Lesion targeting with C dots




First C dot Application: SLN Mapping



mini-swine
whole
body
CT + PET
imaging

^{18}F -FDG



^{124}I -cRGDY-PEG-C-dots



Next IND just approved by FDA




Memorial Sloan-Kettering
Cancer Center

Integr. Biol. 5 (2013), 74




The Future: C dots in Cancer Theranostics

SPRYCEL®
(dasatinib, BMS-354825)



New Particle Platform: Single Pore Cornell Dots


Single-pore sub-10 nm fluorescent silica NPs that can load drugs



drug will be hidden inside



Kai Ma



Precise control over particle architecture and size

K. Ma, H. Sai and U.W. *JACS* **134** (2012), 13180
K. Ma, U.W. et al. *Chem. Mater.* **25** (2013), 677



Start- up: Claymore Technologies

Michelle Bradbury, MD, PhD (MSKCC)
Steve Larson, MD (MSKCC)
Ulrich Wiesner, PhD (Cornell)